Cuevas Diaz Pavel, Nicolini Humberto, Nolasco-Rosales German Alberto, Juarez Rojop Isela, Tovilla-Zarate Carlos Alfonso, Rodriguez Sanchez Ester, Genis-Mendoza Alma Delia
Genomics of Psychiatric and Neurodegenerative Diseases Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City 01090, Mexico.
Biomedical Postgraduate Program, Academic Division of Health Sciences, Juarez Autonomous University of Tabasco, Villahermosa 86000, Mexico.
Biomedicines. 2023 Feb 28;11(3):730. doi: 10.3390/biomedicines11030730.
This study aimed to explore the role of telomere length in three different diabetes types: latent autoimmune diabetes of adulthood (LADA), latent autoimmune diabetes in the young (LADY), and type 2 diabetes mellitus (T2DM). A total of 115 patients were included, 72 (62.61%) had LADA, 30 (26.09%) had T2DM, and 13 (11.30%) had LADY. Telomere length was measured using real-time Polymerase Chain Reaction. For statistical analysis, we used the ANOVA test, X2 test, and the Mann-Whitney U test. Patients with T2DM had higher BMI compared to LADA and LADY groups, with a BMI average of 31.32 kg/m ( = 0.0235). While the LADA group had more patients with comorbidities, there was not a statistically significant difference ( = 0.3164, = 0.3315, = 0.3742 for each of the previously mentioned conditions). There was a difference between those patients with T2DM who took metformin plus any other oral antidiabetic agent and those who took metformin plus insulin, the ones who had longer telomeres. LADA patients had shorter telomeres compared to T2DM patients but not LADY patients. Furthermore, T2DM may have longer telomeres thanks to the protective effects of both metformin and insulin, despite the higher BMI in this group.
成人隐匿性自身免疫性糖尿病（LADA）、青年隐匿性自身免疫性糖尿病（LADY）和2型糖尿病（T2DM）。共纳入115例患者，其中72例（62.61%）患有LADA，30例（26.09%）患有T2DM，13例（11.30%）患有LADY。采用实时聚合酶链反应测量端粒长度。进行统计分析时，我们使用了方差分析、卡方检验和曼-惠特尼U检验。与LADA组和LADY组相比，T2DM患者的体重指数（BMI）更高，BMI平均值为31.32kg/m（P = 0.0235）。虽然LADA组合并症患者更多，但差异无统计学意义（上述每种情况的P值分别为0.3164、0.3315、0.3742）。服用二甲双胍加任何其他口服降糖药的T2DM患者与服用二甲双胍加胰岛素的患者之间存在差异，前者端粒更长。与T2DM患者相比，LADA患者的端粒较短，但与LADY患者相比无差异。此外，尽管T2DM组BMI较高，但由于二甲双胍和胰岛素的保护作用，其端粒可能更长。
